Clinical Trials Logo

Clinical Trial Summary

The COVID-19 pandemic, caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is still raging across the world and vaccination is expected to lead us out of this pandemic. Although the efficacy of these vaccines is beyond doubt, safety still remains a concern. Liver injury, such as autoimmune hepatitis (AIH), has been reported after COVID-19 vaccination. The aim of this prospective study is to investigate the spectrum and profile of liver injury after COVID-19 vaccination in Asia-Pacific region and to explore the potential risk factors for the development of liver injury.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05470894
Study type Observational
Source Humanity & Health Medical Group Limited
Contact George Lau, MD
Phone +852-28613777
Email gkklau@hnhmgl.com
Status Recruiting
Phase
Start date September 5, 2022
Completion date December 31, 2024